Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

Diep Ho,Jessica Huang,Judith-Anne W. Chapman,Kim Leitzel,Suhail M. Ali,Lois E. Shepherd,Wendy R. Parulekar,Catherine E. Ellis,Rocco J. Crescnzo,Liting Zhu,Shakeel Virk,Dora Nomikos,Samuel Aparicio,Karen A. Gelmon,Walter P. Carney,Allan Lipton

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

2017

Diep Ho
Jessica Huang
Judith-Anne W. Chapman
Kim Leitzel
Suhail M. Ali
Lois E. Shepherd
Wendy R. Parulekar
Catherine E. Ellis
Rocco J. Crescnzo
Liting Zhu
Shakeel Virk
Dora Nomikos
Samuel Aparicio
Karen A. Gelmon
Walter P. Carney
Allan Lipton

Background The lapatinib–taxane combination led to shorter PFS than trastuzumab–taxane in HER2+ metastatic breast cancer. We investigated the prognostic and predictive effects of pretreatment serum HER2, CAIX, and TIMP-1.

Keywords:

Trastuzumab
Cancer research
Biomarker (medicine)
Lapatinib
Metastatic breast cancer
Medicine
Survival analysis
Oncology
Internal medicine
Young adult
disease free survival
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations